Related Experiment Videos

[Accelerated atheroma with prednisone and clopidogrel]

Gilles Defuentes1, Stéphane Lecoules, Lionel Vedrine

  • 1Clinique Médicale, Hôpital d'Instruction des Armées du Val de Grâce, Paris. gildef@club-internet.fr

Presse Medicale (Paris, France : 1983)
|March 22, 2006
PubMed

Insights

Corticosteroid therapy and antiplatelet drugs may worsen atheroma by causing intraplaque hemorrhage. This case highlights potential risks in patients with giant cell arteritis and cardiovascular disease.

Area of Science:

  • Cardiovascular Medicine
  • Rheumatology
  • Pathology

Background:

  • Atherosclerosis progression is complex, with potential exacerbation by corticosteroid treatments.
  • Giant cell arteritis (Horton disease) often requires immunosuppressive therapy, including corticosteroids.

Observation:

  • A 68-year-old male smoker with hypercholesterolemia and prior transient ischemic attacks (TIAs) presented with severe Horton disease.
  • Treatment included corticosteroids and azathioprine, with clopidogrel added after a subsequent TIA.
  • Ten months later, severe carotid stenosis was diagnosed, revealing a recent thrombus with necrotic, hemorrhagic, and inflammatory lesions.

Findings:

  • The patient experienced aggravated atheromatous disease, characterized by intraplaque hemorrhage.
  • Contributing factors identified include corticosteroid therapy and antiplatelet treatment (clopidogrel).

Implications:

  • This case underscores the potential for iatrogenic aggravation of atherosclerosis in patients with inflammatory conditions.
  • Careful consideration of combined therapies is crucial to mitigate risks of intraplaque hemorrhage and cerebrovascular events.
Abstract

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...